{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T16:52:40Z","timestamp":1793465560830,"version":"4.5.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"the National Research Foundation of Korea","doi-asserted-by":"crossref","award":["RS-2026-25468517"],"award-info":[{"award-number":["RS-2026-25468517"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"DOI":"10.1007\/s00428-026-04685-x","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:40:54Z","timestamp":1788237654000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Integration of histopathology and molecular features for the classification of benign and malignant hepatocellular neoplasms"],"prefix":"10.1007","author":[{"given":"Christine","family":"Sempoux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0357-7967","authenticated-orcid":false,"given":"Young Nyun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"issue":"7835","key":"4685_CR1","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/s0140-6736(73)92594-4","volume":"2","author":"JK Baum","year":"1973","unstructured":"Baum JK, Bookstein JJ, Holtz F, Klein EW (1973) Possible association between benign hepatomas and oral contraceptives. Lancet 302(7835):926\u2013929. https:\/\/doi.org\/10.1016\/s0140-6736(73)92594-4","journal-title":"Lancet"},{"issue":"9","key":"4685_CR2","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1056\/NEJM197602262940904","volume":"294","author":"HA Edmondson","year":"1976","unstructured":"Edmondson HA, Henderson B, Benton B (1976) Liver-cell adenomas associated with use of oral contraceptives. N Engl J Med 294(9):470\u2013472. https:\/\/doi.org\/10.1056\/NEJM197602262940904","journal-title":"N Engl J Med"},{"issue":"3","key":"4685_CR3","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/hep.21068","volume":"43","author":"J Zucman-Rossi","year":"2006","unstructured":"Zucman-Rossi J, Jeannot E, Nhieu JT et al (2006) Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 43(3):515\u2013524. https:\/\/doi.org\/10.1002\/hep.21068","journal-title":"Hepatology"},{"issue":"3","key":"4685_CR4","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/hep.21743","volume":"46","author":"P Bioulac-Sage","year":"2007","unstructured":"Bioulac-Sage P, Rebouissou S, Thomas C et al (2007) Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology 46(3):740\u2013748. https:\/\/doi.org\/10.1002\/hep.21743","journal-title":"Hepatology"},{"issue":"2","key":"4685_CR5","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/hep.22995","volume":"50","author":"P Bioulac-Sage","year":"2009","unstructured":"Bioulac-Sage P, Laumonier H, Couchy G et al (2009) Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology 50(2):481\u2013489. https:\/\/doi.org\/10.1002\/hep.22995","journal-title":"Hepatology"},{"issue":"4","key":"4685_CR6","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1053\/j.gastro.2016.11.042","volume":"152","author":"JC Nault","year":"2017","unstructured":"Nault JC, Couchy G, Balabaud C et al (2017) Molecular classification of hepatocellular adenoma associates with risk factors, bleeding, and malignant transformation. Gastroenterology 152(4):880-894 e6. https:\/\/doi.org\/10.1053\/j.gastro.2016.11.042","journal-title":"Gastroenterology"},{"issue":"11","key":"4685_CR7","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/s41575-022-00643-5","volume":"19","author":"JC Nault","year":"2022","unstructured":"Nault JC, Paradis V, Ronot M, Zucman-Rossi J (2022) Benign liver tumours: understanding molecular physiology to adapt clinical management. Nat Rev Gastroenterol Hepatol 19(11):703\u2013716. https:\/\/doi.org\/10.1038\/s41575-022-00643-5","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"4685_CR8","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.jhep.2013.10.014","volume":"60","author":"JU Marquardt","year":"2014","unstructured":"Marquardt JU, Seo D, Andersen JB, Gillen MC, Kim MS, Conner EA, Galle PR, Factor VM, Park YN, Thorgeirsson SS (2014) Sequential transcriptome analysis of human liver cancer indicates late stage acquisition of malignant traits. J Hepatol 60(2):346\u2013353. https:\/\/doi.org\/10.1016\/j.jhep.2013.10.014","journal-title":"J Hepatol"},{"key":"4685_CR9","unstructured":"Park YN, Schirmacher P, Mickael T et al (2026) Hepatocellular carcinoma. In: The WHO classification of tumours editorial board (eds) WHO classification of tumours digestive system tumours, 6th edn. International Agency for Research on Cancer (IARC), Lyon pp. 230\u2013237"},{"issue":"6","key":"4685_CR10","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1111\/his.14605","volume":"80","author":"P Bioulac-Sage","year":"2022","unstructured":"Bioulac-Sage P, Gouw ASH, Balabaud C, Sempoux C (2022) Hepatocellular adenoma: what we know, what we do not know, and why it matters. Histopathology 80(6):878\u2013897. https:\/\/doi.org\/10.1111\/his.14605","journal-title":"Histopathology"},{"issue":"9","key":"4685_CR11","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1038\/modpathol.2015.83","volume":"28","author":"T Mounajjed","year":"2015","unstructured":"Mounajjed T, Yasir S, Aleff PA, Torbenson MS (2015) Pigmented hepatocellular adenomas have a high risk of atypia and malignancy. Mod Pathol 28(9):1265\u20131274. https:\/\/doi.org\/10.1038\/modpathol.2015.83","journal-title":"Mod Pathol"},{"issue":"8","key":"4685_CR12","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1097\/PAS.0000000000001711","volume":"45","author":"DJ Rowan","year":"2021","unstructured":"Rowan DJ, Yasir S, Chen ZE et al (2021) Morphologic and molecular findings in myxoid hepatic adenomas. Am J Surg Pathol 45(8):1098\u20131107. https:\/\/doi.org\/10.1097\/PAS.0000000000001711","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"4685_CR13","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.gastro.2003.07.012","volume":"125","author":"Y Bacq","year":"2003","unstructured":"Bacq Y, Jacquemin E, Balabaud C et al (2003) Familial liver adenomatosis associated with hepatocyte nuclear factor 1alpha inactivation. Gastroenterology 125(5):1470\u20131475. https:\/\/doi.org\/10.1016\/j.gastro.2003.07.012","journal-title":"Gastroenterology"},{"issue":"1","key":"4685_CR14","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/1753-0407.12959","volume":"12","author":"A Haddouche","year":"2020","unstructured":"Haddouche A, Bellanne-Chantelot C, Rod A et al (2020) Liver adenomatosis in patients with hepatocyte nuclear factor-1 alpha maturity onset diabetes of the young (HNF1A-MODY): clinical, radiological and pathological characteristics in a French series. J Diabetes 12(1):48\u201357. https:\/\/doi.org\/10.1111\/1753-0407.12959","journal-title":"J Diabetes"},{"issue":"2","key":"4685_CR15","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jhep.2012.09.030","volume":"58","author":"J Calderaro","year":"2013","unstructured":"Calderaro J, Labrune P, Morcrette G et al (2013) Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I. J Hepatol 58(2):350\u2013357. https:\/\/doi.org\/10.1016\/j.jhep.2012.09.030","journal-title":"J Hepatol"},{"issue":"7226","key":"4685_CR16","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/nature07475","volume":"457","author":"S Rebouissou","year":"2009","unstructured":"Rebouissou S, Amessou M, Couchy G, Poussin K, Imbeaud S, Pilati C, Izard T, Balabaud C, Bioulac-Sage P, Zucman-Rossi J (2009) Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 457(7226):200\u2013204. https:\/\/doi.org\/10.1038\/nature07475","journal-title":"Nature"},{"issue":"1","key":"4685_CR17","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jhep.2011.07.018","volume":"56","author":"JC Nault","year":"2012","unstructured":"Nault JC, Fabre M, Couchy G et al (2012) GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. J Hepatol 56(1):184\u2013191. https:\/\/doi.org\/10.1016\/j.jhep.2011.07.018","journal-title":"J Hepatol"},{"issue":"4","key":"4685_CR18","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccr.2014.03.005","volume":"25","author":"C Pilati","year":"2014","unstructured":"Pilati C, Letouze E, Nault JC et al (2014) Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation. Cancer Cell 25(4):428\u2013441. https:\/\/doi.org\/10.1016\/j.ccr.2014.03.005","journal-title":"Cancer Cell"},{"issue":"6","key":"4685_CR19","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1002\/hep.28638","volume":"64","author":"S Rebouissou","year":"2016","unstructured":"Rebouissou S, Franconi A, Calderaro J et al (2016) Genotype-phenotype correlation of CTNNB1 mutations reveals different beta-catenin activity associated with liver tumor progression. Hepatology 64(6):2047\u20132061. https:\/\/doi.org\/10.1002\/hep.28638","journal-title":"Hepatology"},{"key":"4685_CR20","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.humpath.2023.05.010","volume":"138","author":"IA Gonzalez","year":"2023","unstructured":"Gonzalez IA, Torbenson M, Sharifai N, Byrnes K, Chatterjee D, Kakar S, Yeh MM, Wu TT, Zhang X, Jain D (2023) Clinicopathologic characterization of hepatocellular adenomas in men: a multicenter experience. Hum Pathol 138:24\u201333. https:\/\/doi.org\/10.1016\/j.humpath.2023.05.010","journal-title":"Hum Pathol"},{"issue":"4","key":"4685_CR21","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1097\/PAS.0000000000001675","volume":"45","author":"C Sempoux","year":"2021","unstructured":"Sempoux C, Gouw ASH, Dunet V, Paradis V, Balabaud C, Bioulac-Sage P (2021) Predictive patterns of glutamine synthetase immunohistochemical staining in CTNNB1-mutated hepatocellular adenomas. Am J Surg Pathol 45(4):477\u2013487. https:\/\/doi.org\/10.1097\/PAS.0000000000001675","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"4685_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100913","volume":"6","author":"S Di Tommaso","year":"2024","unstructured":"Di Tommaso S, Dourthe C, Dupuy JW et al (2024) Spatial characterisation of beta-catenin-mutated hepatocellular adenoma subtypes by proteomic profiling of the tumour rim. JHEP Rep 6(2):100913. https:\/\/doi.org\/10.1016\/j.jhepr.2023.100913","journal-title":"JHEP Rep"},{"key":"4685_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3218","volume":"4","author":"JC Nault","year":"2013","unstructured":"Nault JC, Mallet M, Pilati C, Calderaro J, Bioulac-Sage P, Laurent C, Laurent A, Cherqui D, Balabaud C, Zucman-Rossi J (2013) High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun 4:2218. https:\/\/doi.org\/10.1038\/ncomms3218","journal-title":"Nat Commun"},{"issue":"9","key":"4685_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2023.100211","volume":"36","author":"N Pote","year":"2023","unstructured":"Pote N, Caruso S, Caderaro J et al (2023) Borderline hepatocellular adenomas: a practical diagnostic approach based on pathologic and molecular features. Mod Pathol 36(9):100211. https:\/\/doi.org\/10.1016\/j.modpat.2023.100211","journal-title":"Mod Pathol"},{"issue":"4","key":"4685_CR25","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s00428-023-03680-w","volume":"484","author":"M Toth","year":"2024","unstructured":"Toth M, Kirchner M, Longerich T, Stenzinger A, Schirmacher P (2024) Integrated genotype-phenotype analysis of familial adenomatous polyposis-associated hepatocellular adenomas. Virchows Arch 484(4):587\u2013595. https:\/\/doi.org\/10.1007\/s00428-023-03680-w","journal-title":"Virchows Arch"},{"issue":"7","key":"4685_CR26","doi-asserted-by":"publisher","first-page":"4649","DOI":"10.1007\/s00330-023-10344-5","volume":"34","author":"A Ducatel","year":"2024","unstructured":"Ducatel A, Trillaud H, Reizine E et al (2024) Sonic hedgehog hepatocellular adenoma: magnetic resonance imaging features and correlation with histology. Eur Radiol 34(7):4649\u20134662. https:\/\/doi.org\/10.1007\/s00330-023-10344-5","journal-title":"Eur Radiol"},{"issue":"6","key":"4685_CR27","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1002\/hep.29336","volume":"66","author":"E Henriet","year":"2017","unstructured":"Henriet E, Abou Hammoud A, Dupuy JW et al (2017) Argininosuccinate synthase 1 (ASS1): a marker of unclassified hepatocellular adenoma and high bleeding risk. Hepatology 66(6):2016\u20132028. https:\/\/doi.org\/10.1002\/hep.29336","journal-title":"Hepatology"},{"issue":"3","key":"4685_CR28","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1002\/hep.29884","volume":"68","author":"JC Nault","year":"2018","unstructured":"Nault JC, Couchy G, Caruso S, Meunier L, Caruana L, Letouze E, Rebouissou S, Paradis V, Calderaro J, Zucman-Rossi J (2018) Argininosuccinate synthase 1 and periportal gene expression in sonic hedgehog hepatocellular adenomas. Hepatology 68(3):964\u2013976. https:\/\/doi.org\/10.1002\/hep.29884","journal-title":"Hepatology"},{"issue":"6","key":"4685_CR29","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1002\/hep4.1514","volume":"4","author":"M Sala","year":"2020","unstructured":"Sala M, Gonzales D, Leste-Lasserre T et al (2020) ASS1 overexpression: a hallmark of sonic hedgehog hepatocellular adenomas. Recommendations for Clinical Practice Hepatol Commun 4(6):809\u2013824. https:\/\/doi.org\/10.1002\/hep4.1514","journal-title":"Recommendations for Clinical Practice Hepatol Commun"},{"issue":"3","key":"4685_CR30","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1002\/hep.31826","volume":"74","author":"C Dourthe","year":"2021","unstructured":"Dourthe C, Julien C, Di Tommaso S et al (2021) Proteomic profiling of hepatocellular adenomas paves the way to diagnostic and prognostic approaches. Hepatology 74(3):1595\u20131610. https:\/\/doi.org\/10.1002\/hep.31826","journal-title":"Hepatology"},{"issue":"5","key":"4685_CR31","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.humpath.2012.07.019","volume":"44","author":"KJ Evason","year":"2013","unstructured":"Evason KJ, Grenert JP, Ferrell LD, Kakar S (2013) Atypical hepatocellular adenoma-like neoplasms with beta-catenin activation show cytogenetic alterations similar to well-differentiated hepatocellular carcinomas. Hum Pathol 44(5):750\u2013758. https:\/\/doi.org\/10.1016\/j.humpath.2012.07.019","journal-title":"Hum Pathol"},{"issue":"3","key":"4685_CR32","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.humpath.2013.09.020","volume":"45","author":"P Bedossa","year":"2014","unstructured":"Bedossa P, Burt AD, Brunt EM et al (2014) Well-differentiated hepatocellular neoplasm of uncertain malignant potential: proposal for a new diagnostic category. Hum Pathol 45(3):658\u2013660. https:\/\/doi.org\/10.1016\/j.humpath.2013.09.020","journal-title":"Hum Pathol"},{"issue":"11","key":"4685_CR33","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1038\/s41379-019-0282-0","volume":"32","author":"NM Joseph","year":"2019","unstructured":"Joseph NM, Umetsu SE, Shafizadeh N, Ferrell L, Kakar S (2019) Genomic profiling of well-differentiated hepatocellular neoplasms with diffuse glutamine synthetase staining reveals similar genetics across the adenoma to carcinoma spectrum. Mod Pathol 32(11):1627\u20131636. https:\/\/doi.org\/10.1038\/s41379-019-0282-0","journal-title":"Mod Pathol"},{"issue":"1","key":"4685_CR34","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/hep.29762","volume":"68","author":"M Ziol","year":"2018","unstructured":"Ziol M, Pote N, Amaddeo G et al (2018) Macrotrabecular-massive hepatocellular carcinoma: a distinctive histological subtype with clinical relevance. Hepatology 68(1):103\u2013112. https:\/\/doi.org\/10.1002\/hep.29762","journal-title":"Hepatology"},{"issue":"4","key":"4685_CR35","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.jhep.2017.05.014","volume":"67","author":"J Calderaro","year":"2017","unstructured":"Calderaro J, Couchy G, Imbeaud S et al (2017) Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. J Hepatol 67(4):727\u2013738. https:\/\/doi.org\/10.1016\/j.jhep.2017.05.014","journal-title":"J Hepatol"},{"key":"4685_CR36","doi-asserted-by":"publisher","first-page":"717","DOI":"10.2147\/JHC.S373960","volume":"9","author":"Y Shan","year":"2022","unstructured":"Shan Y, Yu X, Yang Y, Sun J, Wu S, Mao S, Lu C (2022) Nomogram for the preoperative prediction of the macrotrabecular-massive subtype of hepatocellular carcinoma. J Hepatocell Carcinoma 9:717\u2013728. https:\/\/doi.org\/10.2147\/JHC.S373960","journal-title":"J Hepatocell Carcinoma"},{"key":"4685_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115955","volume":"170","author":"C Guo","year":"2024","unstructured":"Guo C, Zhou N, Lu Y et al (2024) FGF19\/FGFR4 signaling contributes to hepatocellular carcinoma survival and immune escape by regulating IGF2BP1-mediated expression of PD-L1. Biomed Pharmacother 170:115955. https:\/\/doi.org\/10.1016\/j.biopha.2023.115955","journal-title":"Biomed Pharmacother"},{"issue":"19","key":"4685_CR38","doi-asserted-by":"publisher","first-page":"5859","DOI":"10.1158\/1078-0432.CCR-19-0859","volume":"25","author":"J Calderaro","year":"2019","unstructured":"Calderaro J, Meunier L, Nguyen CT et al (2019) ESM1 as a marker of macrotrabecular-massive hepatocellular carcinoma. Clin Cancer Res 25(19):5859\u20135865. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-0859","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4685_CR39","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/hep.30814","volume":"71","author":"SL Renne","year":"2020","unstructured":"Renne SL, Woo HY, Allegra S et al (2020) Vessels encapsulating tumor clusters (VETC) is a powerful predictor of aggressive hepatocellular carcinoma. Hepatology 71(1):183\u2013195. https:\/\/doi.org\/10.1002\/hep.30814","journal-title":"Hepatology"},{"issue":"1","key":"4685_CR40","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/hep.30162","volume":"69","author":"SH Liao","year":"2019","unstructured":"Liao SH, Su TH, Jeng YM, Liang PC, Chen DS, Chen CH, Kao JH (2019) Clinical manifestations and outcomes of patients with sarcomatoid hepatocellular carcinoma. Hepatology 69(1):209\u2013221. https:\/\/doi.org\/10.1002\/hep.30162","journal-title":"Hepatology"},{"issue":"2","key":"4685_CR41","doi-asserted-by":"publisher","first-page":"426","DOI":"10.3350\/cmh.2024.0686","volume":"31","author":"RQ Sun","year":"2025","unstructured":"Sun RQ, Ye YH, Xu Y et al (2025) Integrated molecular characterization of sarcomatoid hepatocellular carcinoma. Clin Mol Hepatol 31(2):426\u2013444. https:\/\/doi.org\/10.3350\/cmh.2024.0686","journal-title":"Clin Mol Hepatol"},{"issue":"3","key":"4685_CR42","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1002\/ijc.33545","volume":"149","author":"R Morisue","year":"2021","unstructured":"Morisue R, Kojima M, Suzuki T et al (2021) Sarcomatoid hepatocellular carcinoma is distinct from ordinary hepatocellular carcinoma: clinicopathologic, transcriptomic and immunologic analyses. Int J Cancer 149(3):546\u2013560. https:\/\/doi.org\/10.1002\/ijc.33545","journal-title":"Int J Cancer"},{"key":"4685_CR43","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.humpath.2020.12.009","volume":"112","author":"MS Torbenson","year":"2021","unstructured":"Torbenson MS (2021) Hepatocellular carcinoma: making sense of morphological heterogeneity, growth patterns, and subtypes. Hum Pathol 112:86\u2013101. https:\/\/doi.org\/10.1016\/j.humpath.2020.12.009","journal-title":"Hum Pathol"},{"issue":"5","key":"4685_CR44","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1111\/j.1478-3231.2007.01468.x","volume":"27","author":"K Araki","year":"2007","unstructured":"Araki K, Kishihara F, Takahashi K, Matsumata T, Shimura T, Suehiro T, Kuwano H (2007) Hepatocellular carcinoma producing a granulocyte colony-stimulating factor: report of a resected case with a literature review. Liver Int 27(5):716\u2013721. https:\/\/doi.org\/10.1111\/j.1478-3231.2007.01468.x","journal-title":"Liver Int"},{"issue":"11","key":"4685_CR45","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1097\/PAS.0b013e3181f31caa","volume":"34","author":"M Salomao","year":"2010","unstructured":"Salomao M, Yu WM, Brown RS Jr., Emond JC, Lefkowitch JH (2010) Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD\/NASH. Am J Surg Pathol 34(11):1630\u20131636. https:\/\/doi.org\/10.1097\/PAS.0b013e3181f31caa","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"4685_CR46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0171922","volume":"12","author":"JS Lee","year":"2017","unstructured":"Lee JS, Yoo JE, Kim H, Rhee H, Koh MJ, Nahm JH, Choi JS, Lee KH, Park YN (2017) Tumor stroma with senescence-associated secretory phenotype in steatohepatitic hepatocellular carcinoma. PLoS ONE 12(3):e0171922. https:\/\/doi.org\/10.1371\/journal.pone.0171922","journal-title":"PLoS ONE"},{"key":"4685_CR47","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.humpath.2024.06.007","volume":"149","author":"GST Soon","year":"2024","unstructured":"Soon GST, Callea F, Burt AD et al (2024) Steatohepatitic hepatocellular carcinoma: a new approach to classifying morphological subtypes of hepatocellular carcinoma. Hum Pathol 149:55\u201365. https:\/\/doi.org\/10.1016\/j.humpath.2024.06.007","journal-title":"Hum Pathol"},{"issue":"1","key":"4685_CR48","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/modpathol.2017.103","volume":"31","author":"RP Graham","year":"2018","unstructured":"Graham RP, Yeh MM, Lam-Himlin D et al (2018) Molecular testing for the clinical diagnosis of fibrolamellar carcinoma. Mod Pathol 31(1):141\u2013149. https:\/\/doi.org\/10.1038\/modpathol.2017.103","journal-title":"Mod Pathol"},{"issue":"12","key":"4685_CR49","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1038\/modpathol.2013.68","volume":"26","author":"LD Wood","year":"2013","unstructured":"Wood LD, Heaphy CM, Daniel HD et al (2013) Chromophobe hepatocellular carcinoma with abrupt anaplasia: a proposal for a new subtype of hepatocellular carcinoma with unique morphological and molecular features. Mod Pathol 26(12):1586\u20131593. https:\/\/doi.org\/10.1038\/modpathol.2013.68","journal-title":"Mod Pathol"},{"issue":"10","key":"4685_CR50","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1111\/liv.14975","volume":"41","author":"HJ Kang","year":"2021","unstructured":"Kang HJ, Oh JH, Kim YW et al (2021) Clinicopathological and molecular characterization of chromophobe hepatocellular carcinoma. Liver Int 41(10):2499\u20132510. https:\/\/doi.org\/10.1111\/liv.14975","journal-title":"Liver Int"},{"issue":"1","key":"4685_CR51","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jhep.2018.09.003","volume":"70","author":"J Calderaro","year":"2019","unstructured":"Calderaro J, Petitprez F, Becht E et al (2019) Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma. J Hepatol 70(1):58\u201365. https:\/\/doi.org\/10.1016\/j.jhep.2018.09.003","journal-title":"J Hepatol"},{"issue":"5","key":"4685_CR52","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1111\/liv.15865","volume":"44","author":"B Ahn","year":"2024","unstructured":"Ahn B, Ahn HS, Shin J et al (2024) Characterization of lymphocyte-rich hepatocellular carcinoma and the prognostic role of tertiary lymphoid structures. Liver Int 44(5):1202\u20131218. https:\/\/doi.org\/10.1111\/liv.15865","journal-title":"Liver Int"},{"issue":"7","key":"4685_CR53","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1245\/s10434-010-1540-z","volume":"18","author":"T Li","year":"2011","unstructured":"Li T, Fan J, Qin LX, Zhou J, Sun HC, Qiu SJ, Ye QH, Wang L, Tang ZY (2011) Risk factors, prognosis, and management of early and late intrahepatic recurrence after resection of primary clear cell carcinoma of the liver. Ann Surg Oncol 18(7):1955\u20131963. https:\/\/doi.org\/10.1245\/s10434-010-1540-z","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"4685_CR54","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1002\/hep.25570","volume":"55","author":"JY Seok","year":"2012","unstructured":"Seok JY, Na DC, Woo HG et al (2012) A fibrous stromal component in hepatocellular carcinoma reveals a cholangiocarcinoma-like gene expression trait and epithelial-mesenchymal transition. Hepatology 55(6):1776\u20131786. https:\/\/doi.org\/10.1002\/hep.25570","journal-title":"Hepatology"},{"key":"4685_CR55","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.humpath.2018.11.024","volume":"86","author":"M Hatano","year":"2019","unstructured":"Hatano M, Ojima H, Masugi Y, Tsujikawa H, Hiraoka N, Kanai Y, Shimada K, Shinoda M, Sakamoto M (2019) Steatotic and nonsteatotic scirrhous hepatocellular carcinomas reveal distinct clinicopathological features. Hum Pathol 86:222\u2013232. https:\/\/doi.org\/10.1016\/j.humpath.2018.11.024","journal-title":"Hum Pathol"},{"issue":"8","key":"4685_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100792","volume":"5","author":"K Liu","year":"2023","unstructured":"Liu K, Dennis C, Prince DS, Marsh-Wakefield F, Santhakumar C, Gamble JR, Strasser SI, McCaughan GW (2023) Vessels that encapsulate tumour clusters vascular pattern in hepatocellular carcinoma. JHEP Rep 5(8):100792. https:\/\/doi.org\/10.1016\/j.jhepr.2023.100792","journal-title":"JHEP Rep"},{"issue":"1","key":"4685_CR57","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12967-025-07354-w","volume":"24","author":"Y Zhu","year":"2026","unstructured":"Zhu Y, Wang M, Cao J, Song H, Zhang P (2026) Vessels encapsulating tumor clusters in hepatocellular carcinoma: a distinct metastatic pathway with diagnostic and therapeutic significance. J Transl Med 24(1):185. https:\/\/doi.org\/10.1186\/s12967-025-07354-w","journal-title":"J Transl Med"},{"issue":"4","key":"4685_CR58","doi-asserted-by":"publisher","DOI":"10.1172\/JCI193758","volume":"136","author":"BY Huang","year":"2026","unstructured":"Huang BY, Mi ZQ, Zhang XY et al (2026) Vessels encapsulating tumor clusters promote noninvasive metastasis of hepatocellular carcinoma by shaping an immunosuppressive microenvironment. J Clin Invest 136(4):e193758. https:\/\/doi.org\/10.1172\/JCI193758","journal-title":"J Clin Invest"},{"issue":"3","key":"4685_CR59","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1002\/hep.30366","volume":"70","author":"JH Fang","year":"2019","unstructured":"Fang JH, Xu L, Shang LR et al (2019) Vessels that encapsulate tumor clusters (VETC) pattern is a predictor of sorafenib benefit in patients with hepatocellular carcinoma. Hepatology 70(3):824\u2013839. https:\/\/doi.org\/10.1002\/hep.30366","journal-title":"Hepatology"},{"issue":"3","key":"4685_CR60","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1159\/000547669","volume":"15","author":"C De Carlo","year":"2025","unstructured":"De Carlo C, Akpinar R, Durante B et al (2025) Vessels that encapsulate tumor cluster+ unresectable hepatocellular carcinomas benefit of antiangiogenic therapy. Liver Cancer 15(3):394\u2013407. https:\/\/doi.org\/10.1159\/000547669","journal-title":"Liver Cancer"},{"issue":"7","key":"4685_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2026.101874","volume":"8","author":"A Sayadi","year":"2026","unstructured":"Sayadi A, Campani C, Laurent-Bellue A et al (2026) Vessels encapsulating tumor clusters predict better outcomes in advanced hepatocellular carcinoma treated with atezolizumab-bevacizumab. JHEP Rep 8(7):101874. https:\/\/doi.org\/10.1016\/j.jhepr.2026.101874","journal-title":"JHEP Rep"},{"key":"4685_CR62","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.humpath.2021.09.009","volume":"119","author":"M Torbenson","year":"2022","unstructured":"Torbenson M, McCabe CE, O\u2019Brien DR et al (2022) Morphological heterogeneity in beta-catenin-mutated hepatocellular carcinomas: implications for tumor molecular classification. Hum Pathol 119:15\u201327. https:\/\/doi.org\/10.1016\/j.humpath.2021.09.009","journal-title":"Hum Pathol"},{"issue":"5","key":"4685_CR63","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1053\/j.gastro.2015.05.061","volume":"149","author":"J Zucman-Rossi","year":"2015","unstructured":"Zucman-Rossi J, Villanueva A, Nault JC, Llovet JM (2015) Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology 149(5):1226\u20131239.e4. https:\/\/doi.org\/10.1053\/j.gastro.2015.05.061","journal-title":"Gastroenterology"},{"issue":"8","key":"4685_CR64","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1158\/2159-8290.CD-19-0074","volume":"9","author":"M Ruiz de Galarreta","year":"2019","unstructured":"Ruiz de Galarreta M, Bresnahan E, Molina-Sanchez P et al (2019) beta-catenin activation promotes immune escape and resistance to Anti-PD-1 therapy in hepatocellular carcinoma. Cancer Discov 9(8):1124\u20131141. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0074","journal-title":"Cancer Discov"},{"issue":"5","key":"4685_CR65","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1002\/hep.24559","volume":"54","author":"H Kim","year":"2011","unstructured":"Kim H, Choi GH, Na DC, Ahn EY, Kim GI, Lee JE, Cho JY, Yoo JE, Choi JS, Park YN (2011) Human hepatocellular carcinomas with \u201cStemness\u201d-related marker expression: keratin 19 expression and a poor prognosis. Hepatology 54(5):1707\u20131717. https:\/\/doi.org\/10.1002\/hep.24559","journal-title":"Hepatology"},{"issue":"6","key":"4685_CR66","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1159\/000510522","volume":"9","author":"H Rhee","year":"2020","unstructured":"Rhee H, Kim H, Park YN (2020) Clinico-radio-pathological and molecular features of hepatocellular carcinomas with keratin 19 expression. Liver Cancer (Basel) 9(6):663\u2013681. https:\/\/doi.org\/10.1159\/000510522","journal-title":"Liver Cancer (Basel)"},{"issue":"59","key":"4685_CR67","doi-asserted-by":"publisher","first-page":"99359","DOI":"10.18632\/oncotarget.22078","volume":"8","author":"JH Nahm","year":"2017","unstructured":"Nahm JH, Rhee H, Kim H, Yoo JE, San Lee J, Jeon Y, Choi GH, Park YN (2017) Increased expression of stemness markers and altered tumor stroma in hepatocellular carcinoma under TACE-induced hypoxia: a biopsy and resection matched study. Oncotarget 8(59):99359\u201399371. https:\/\/doi.org\/10.18632\/oncotarget.22078","journal-title":"Oncotarget"},{"issue":"7","key":"4685_CR68","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1158\/0008-5472.CAN-17-0988","volume":"78","author":"H Rhee","year":"2018","unstructured":"Rhee H, Kim HY, Choi JH, Woo HG, Yoo JE, Nahm JH, Choi JS, Park YN (2018) Keratin 19 expression in hepatocellular carcinoma is regulated by fibroblast-derived HGF via a MET-ERK1\/2-AP1 and SP1 axis. Cancer Res 78(7):1619\u20131631. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-0988","journal-title":"Cancer Res"},{"issue":"6","key":"4685_CR69","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1002\/hep.28710","volume":"64","author":"J Calderaro","year":"2016","unstructured":"Calderaro J, Rousseau B, Amaddeo G et al (2016) Programmed death ligand 1 expression in hepatocellu lar carcinoma: Relationship With clinical and pathological features. Hepatology 64(6):2038\u20132046. https:\/\/doi.org\/10.1002\/hep.28710","journal-title":"Hepatology"},{"issue":"9","key":"4685_CR70","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1038\/modpathol.2016.111","volume":"29","author":"H Rhee","year":"2016","unstructured":"Rhee H, Nahm JH, Kim H, Choi GH, Yoo JE, Lee HS, Koh MJ, Park YN (2016) Poor outcome of hepatocellular carcinoma with stemness marker under hypoxia: resistance to transarterial chemoembolization. Mod Pathol 29(9):1038\u20131049. https:\/\/doi.org\/10.1038\/modpathol.2016.111","journal-title":"Mod Pathol"},{"issue":"6","key":"4685_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101078","volume":"6","author":"I Scheers","year":"2024","unstructured":"Scheers I, Tambucci R, De Magnee C, Pire A, Stephenne X, Reding R, Nault JC (2024) Paediatric hepatocellular adenomas: lessons from a systematic review of relevant literature. JHEP Rep 6(6):101078. https:\/\/doi.org\/10.1016\/j.jhepr.2024.101078","journal-title":"JHEP Rep"},{"issue":"6","key":"4685_CR72","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1097\/PAS.0000000000001892","volume":"46","author":"S Yasir","year":"2022","unstructured":"Yasir S, Chen ZE, Jain D, Kakar S, Wu TT, Yeh MM, Torbenson MS (2022) Hepatic adenomas in patients 60 and older are enriched for HNF1A inactivation and malignant transformation. Am J Surg Pathol 46(6):786\u2013792. https:\/\/doi.org\/10.1097\/PAS.0000000000001892","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"4685_CR73","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.jhep.2015.06.017","volume":"63","author":"C Sempoux","year":"2015","unstructured":"Sempoux C, Paradis V, Komuta M, Wee A, Calderaro J, Balabaud C, Quaglia A, Bioulac-Sage P (2015) Hepatocellular nodules expressing markers of hepatocellular adenomas in Budd-Chiari syndrome and other rare hepatic vascular disorders. J Hepatol 63(5):1173\u20131180. https:\/\/doi.org\/10.1016\/j.jhep.2015.06.017","journal-title":"J Hepatol"},{"key":"4685_CR74","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.humpath.2016.02.025","volume":"53","author":"T Sorkin","year":"2016","unstructured":"Sorkin T, Strautnieks S, Foskett P, Peddu P, Thompson RJ, Heaton N, Quaglia A (2016) Multiple beta-catenin mutations in hepatocellular lesions arising in Abernethy malformation. Hum Pathol 53:153\u2013158. https:\/\/doi.org\/10.1016\/j.humpath.2016.02.025","journal-title":"Hum Pathol"},{"key":"4685_CR75","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.humpath.2023.09.010","volume":"142","author":"SE Umetsu","year":"2023","unstructured":"Umetsu SE, Joseph NM, Cho SJ, Morotti R, Deshpande V, Jain D, Kakar S (2023) Focal nodular hyperplasia-like nodules arising in the setting of hepatic vascular disorders with portosystemic shunting show beta-catenin activation. Hum Pathol 142:20\u201326. https:\/\/doi.org\/10.1016\/j.humpath.2023.09.010","journal-title":"Hum Pathol"},{"issue":"5","key":"4685_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2026.101778","volume":"8","author":"C Sempoux","year":"2026","unstructured":"Sempoux C, Alves VA, Arola J et al (2026) New histopathological terminology for well-differentiated hepatocellular lesions in unusual clinico-pathological scenarios: HCA-like and FNH-like. JHEP Rep 8(5):101778. https:\/\/doi.org\/10.1016\/j.jhepr.2026.101778","journal-title":"JHEP Rep"},{"key":"4685_CR77","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2026.0431","author":"H Rhee","year":"2026","unstructured":"Rhee H, Park YN (2026) Comprehensive radio pathological and molecular review of HCC: expanding on the WHO, 6th edition. Clin Mol Hepatol. https:\/\/doi.org\/10.3350\/cmh.2026.0431","journal-title":"Clin Mol Hepatol"},{"issue":"6","key":"4685_CR78","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.jhep.2024.12.016","volume":"82","author":"S Cappuyns","year":"2025","unstructured":"Cappuyns S, Pique-Gili M, Esteban-Fabro R et al (2025) Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma. J Hepatol 82(6):1036\u20131049. https:\/\/doi.org\/10.1016\/j.jhep.2024.12.016","journal-title":"J Hepatol"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-026-04685-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-026-04685-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-026-04685-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:41:09Z","timestamp":1788237669000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-026-04685-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":78,"alternative-id":["4685"],"URL":"https:\/\/doi.org\/10.1007\/s00428-026-04685-x","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"assertion":[{"value":"29 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"YN Park and C Sempoux have no competing interests to declare that are relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}